AI drug discovery company Reverie Labs has sold its key assets to cell programming and biosecurity company Ginkgo Bioworks for an undisclosed sum.
The acquisition will incorporate Reverie's models, software, and workflows into Ginkgo’s system, further expanding its AI/ML capabilities for experimental design and supporting its small molecule programs. Ginkgo will leverage the Reverie Labs assets to boost the company’s AI/ML-based discovery services.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.